Xospata for Relapsed or Refractory AML

Xospata (gilteritinib, Astellas)

Indications: Adult patients with relapsed or refractor acute myeloid leukemia (AML) with an FLT3 mutation.

Dosage: 120 mg orally once-daily; 40 mg tablets

Contraindications: Hypersensitivity to gilteritinib or any of the excipients. Naphylactic reactions have been observed in clinical trials.

Click here for more prescribing information